TY - JOUR
T1 - Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
AU - Staff, Nathan P.
AU - Jones, David T.
AU - Singer, Wolfgang
N1 - Publisher Copyright:
© 2019 Mayo Foundation for Medical Education and Research
PY - 2019/5
Y1 - 2019/5
N2 - Mesenchymal stromal cells are multipotent cells that are being used to treat a variety of medical conditions. Over the past decade, there has been considerable excitement about using MSCs to treat neurodegenerative diseases, which are diseases that are typically fatal and without other robust therapies. In this review, we discuss the proposed MSC mechanisms of action in neurodegenerative diseases, which include growth factor secretion, exosome secretion, and attenuation of neuroinflammation. We then provide a summary of preclinical and early clinical work on MSC therapies in amyotrophic lateral sclerosis, multiple system atrophy, Parkinson disease, and Alzheimer disease. Continued rigorous and controlled studies of MSC therapies will be critical in order to establish efficacy and protect patients from possible untoward effects.
AB - Mesenchymal stromal cells are multipotent cells that are being used to treat a variety of medical conditions. Over the past decade, there has been considerable excitement about using MSCs to treat neurodegenerative diseases, which are diseases that are typically fatal and without other robust therapies. In this review, we discuss the proposed MSC mechanisms of action in neurodegenerative diseases, which include growth factor secretion, exosome secretion, and attenuation of neuroinflammation. We then provide a summary of preclinical and early clinical work on MSC therapies in amyotrophic lateral sclerosis, multiple system atrophy, Parkinson disease, and Alzheimer disease. Continued rigorous and controlled studies of MSC therapies will be critical in order to establish efficacy and protect patients from possible untoward effects.
UR - http://www.scopus.com/inward/record.url?scp=85064759751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064759751&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2019.01.001
DO - 10.1016/j.mayocp.2019.01.001
M3 - Review article
C2 - 31054608
AN - SCOPUS:85064759751
SN - 0025-6196
VL - 94
SP - 892
EP - 905
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 5
ER -